Quantcast

Industry news that matters to you.  Learn more

Test Could Identify Which Prostate Cancers Require Treatment

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Use of this three-gene biomarker, in conjunction with existing cancer-staging tests, could help physicians better determine which men with early prostate cancer can be safely followed with “active surveillance” and spared the risks of prostate removal or other invasive treatment. The findings were published recently in the online edition of Science Translational Medicine.

New Link Between Growth Factors and Early Prostate Cancer Found

A new study by researchers from the University of Bristol, presented at the National Cancer Research Institute (NCRI) conference today, has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

The Cancer Biomarker Conundrum: Too Many False Discoveries

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.